Literature DB >> 23160324

Targeting MEK for the treatment of non-small-cell lung cancer.

Jonathan W Goldman1, Edward B Garon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23160324      PMCID： PMC3741037          DOI： 10.1097/JTO.0b013e31826df0bc

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  12 in total

1.  Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.

Authors:  Edward B Garon; Richard S Finn; Wylie Hosmer; Judy Dering; Charles Ginther; Shahriar Adhami; Naeimeh Kamranpour; Sharon Pitts; Amrita Desai; David Elashoff; Tim French; Paul Smith; Dennis J Slamon
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

2.  A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

Authors:  Eric B Haura; Alejandro D Ricart; Timothy G Larson; Philip J Stella; Lyudmila Bazhenova; Vincent A Miller; Roger B Cohen; Peter D Eisenberg; Paulina Selaru; Keith D Wilner; Shirish M Gadgeel
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

3.  MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Authors:  Hiroshi Hirai; Hiroshi Sootome; Yoko Nakatsuru; Katsuyoshi Miyama; Shunsuke Taguchi; Kyoko Tsujioka; Yoko Ueno; Harold Hatch; Pradip K Majumder; Bo-Sheng Pan; Hidehito Kotani
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

4.  Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

Authors:  Jonathan R Dry; Sandra Pavey; Christine A Pratilas; Chris Harbron; Sarah Runswick; Darren Hodgson; Christine Chresta; Rose McCormack; Natalie Byrne; Mark Cockerill; Alexander Graham; Garry Beran; Andrew Cassidy; Carolyn Haggerty; Helen Brown; Gillian Ellison; Judy Dering; Barry S Taylor; Mitchell Stark; Vanessa Bonazzi; Sugandha Ravishankar; Leisl Packer; Feng Xing; David B Solit; Richard S Finn; Neal Rosen; Nicholas K Hayward; Tim French; Paul D Smith
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

5.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

6.  Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.

Authors:  T Mitsudomi; J Viallet; J L Mulshine; R I Linnoila; J D Minna; A F Gazdar
Journal:  Oncogene       Date:  1991-08       Impact factor: 9.867

7.  A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.

Authors:  John D Hainsworth; Cristina L Cebotaru; Vladimir Kanarev; Tudor E Ciuleanu; Danail Damyanov; Phillip Stella; Hristo Ganchev; Gillian Pover; Clive Morris; Valentina Tzekova
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

8.  GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.

Authors:  Aidan G Gilmartin; Maureen R Bleam; Arthur Groy; Katherine G Moss; Elisabeth A Minthorn; Swarupa G Kulkarni; Cynthia M Rominger; Symon Erskine; Kelly E Fisher; Jingsong Yang; Francesca Zappacosta; Roland Annan; David Sutton; Sylvie G Laquerre
Journal:  Clin Cancer Res       Date:  2011-01-18       Impact factor: 12.531

9.  Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.

Authors:  Jieru Meng; Bingbing Dai; Bingliang Fang; B Nebiyou Bekele; William G Bornmann; Duoli Sun; Zhenghong Peng; Roy S Herbst; Vassiliki Papadimitrakopoulou; John D Minna; Michael Peyton; Jack A Roth
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

Authors:  Alex A Adjei; Roger B Cohen; Wilbur Franklin; Clive Morris; David Wilson; Julian R Molina; Lorelei J Hanson; Lia Gore; Laura Chow; Stephen Leong; Lara Maloney; Gilad Gordon; Heidi Simmons; Allison Marlow; Kevin Litwiler; Suzy Brown; Gregory Poch; Katie Kane; Jerry Haney; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2008-04-07       Impact factor: 44.544
View more
  6 in total

1.  Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old.

Authors:  Ting Ye; Yunjian Pan; Rui Wang; Haichuan Hu; Yang Zhang; Hang Li; Lei Wang; Yihua Sun; Haiquan Chen
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 2.  KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.

Authors:  Javier de Castro Carpeño; Cristóbal Belda-Iniesta
Journal:  Transl Lung Cancer Res       Date:  2013-04

3.  Clinical next generation sequencing to identify actionable aberrations in a phase I program.

Authors:  Genevieve M Boland; Sarina A Piha-Paul; Vivek Subbiah; Mark Routbort; Shelley M Herbrich; Keith Baggerly; Keyur P Patel; Lauren Brusco; Chacha Horombe; Aung Naing; Siqing Fu; David S Hong; Filip Janku; Amber Johnson; Russell Broaddus; Raja Luthra; Kenna Shaw; John Mendelsohn; Gordon B Mills; Funda Meric-Bernstam
Journal:  Oncotarget       Date:  2015-08-21

4.  PAGER 2.0: an update to the pathway, annotated-list and gene-signature electronic repository for Human Network Biology.

Authors:  Zongliang Yue; Qi Zheng; Michael T Neylon; Minjae Yoo; Jimin Shin; Zhiying Zhao; Aik Choon Tan; Jake Y Chen
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

Review 5.  Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

Authors:  Marzia Del Re; Eleonora Rofi; Giuliana Restante; Stefania Crucitta; Elena Arrigoni; Stefano Fogli; Massimo Di Maio; Iacopo Petrini; Romano Danesi
Journal:  Oncotarget       Date:  2017-12-21

6.  MiRNA therapeutics based on logic circuits of biological pathways.

Authors:  Valeria Boscaino; Antonino Fiannaca; Laura La Paglia; Massimo La Rosa; Riccardo Rizzo; Alfonso Urso
Journal:  BMC Bioinformatics       Date:  2019-11-22       Impact factor: 3.169
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.